| SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES |
The
table below summarizes the significant expense categories regularly reviewed by the CODM:
SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| | |
For the three months ended June 30, | | |
For the six months ended June 30, | |
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| | |
| | |
| | |
| | |
| |
| License and other revenues | |
$ | 400 | | |
$ | — | | |
$ | 400 | | |
$ | — | |
| | |
| | | |
| | | |
| | | |
| | |
| Research and development costs | |
| | | |
| | | |
| | | |
| | |
| Salaries & related costs | |
$ | 2,235 | | |
$ | 4,441 | | |
$ | 6,916 | | |
$ | 7,996 | |
| Non-cash stock-based compensation | |
| 232 | | |
| 224 | | |
| 902 | | |
| 570 | |
| Other research and development costs (a) | |
| 3,476 | | |
| 4,553 | | |
| 8,066 | | |
| 7,859 | |
| Total research and development costs | |
$ | 5,943 | | |
$ | 9,218 | | |
$ | 15,884 | | |
$ | 16,425 | |
| | |
| | | |
| | | |
| | | |
| | |
| Selling, general and administrative costs | |
| | | |
| | | |
| | | |
| | |
| Salaries & related costs | |
$ | 4,670 | | |
$ | 3,434 | | |
$ | 8,323 | | |
$ | 5,696 | |
| Non-cash stock-based compensation | |
| 2,598 | | |
| 1,099 | | |
| 4,629 | | |
| 2,299 | |
| Pre-commercial preparation costs | |
| 2,290 | | |
| 1,460 | | |
| 3,497 | | |
| 2,811 | |
| Regulatory and production costs | |
| 4,855 | | |
| — | | |
| 4,855 | | |
| — | |
| Other selling, general and administrative costs (b) | |
| 2,736 | | |
| 2,653 | | |
| 5,631 | | |
| 4,963 | |
| Total selling, general and administrative costs | |
$ | 17,149 | | |
$ | 8,646 | | |
$ | 26,935 | | |
$ | 15,769 | |
| | |
| | | |
| | | |
| | | |
| | |
| Other segment items (c) | |
| (131,525 | ) | |
| (25,270 | ) | |
| (139,223 | ) | |
| (8,022 | ) |
| Net income (loss) | |
$ | 108,833 | | |
$ | 7,406 | | |
$ | 96,804 | | |
$ | (24,172 | ) |
| (a) |
Other
research and development expenses include, but are not limited to preclinical lab supplies, preclinical and development costs, clinical
trial costs, preclinical manufacturing and manufacturing facility costs, costs associated with preclinical regulatory approvals,
preclinical depreciation on lab supplies and manufacturing facilities, and preclinical consultant-related expenses. |
| (b) |
Other
general and administrative expenses primarily consist of office facility costs, public reporting company related costs, professional
fees (e.g., legal expenses) and other general operating expenses not otherwise included in research and development expenses. |
| (c) |
Other
segment items includes royalties, interest income, interest expense, change in fair value of warrant and derivative liabilities,
gain on sale of priority review voucher, other income and income tax expense. |
|